- Home
- AMZN vs MRK Comparison
AMZN vs MRK Comparison
Compare AMZN & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZN | MRK |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1T | 268.7B |
| IPO Year | 1997 | 1994 |
Fundamental Metrics
Financial Performance| Metric | AMZN | MRK |
|---|---|---|
| Price | $249.13 | $119.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 44 | 17 |
| Target Price | ★ $279.45 | $125.59 |
| AVG Volume (30 Days) | ★ 34.0M | 6.5M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.83% |
| EPS Growth | ★ 29.66 | 8.01 |
| EPS | 7.17 | ★ 7.28 |
| Revenue | ★ $716,924,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $14.63 | $3.73 |
| Revenue Next Year | $11.84 | $5.42 |
| P/E Ratio | $33.47 | ★ $16.50 |
| Revenue Growth | ★ 12.38 | 1.31 |
| 52 Week Low | $165.29 | $75.40 |
| 52 Week High | $258.60 | $125.14 |
Technical Indicators
Market Signals| Indicator | AMZN | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 75.97 | 52.09 |
| Support Level | $216.70 | $113.27 |
| Resistance Level | $258.60 | $125.14 |
| Average True Range (ATR) | 6.02 | 2.70 |
| MACD | 4.64 | 0.10 |
| Stochastic Oscillator | 93.88 | 44.00 |
Price Performance
Historical ComparisonAbout AMZN Amazon.com Inc.
Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 74% of total, followed by Amazon Web Services (17%), and advertising services (9%). International segments constitute 22% of Amazon's total revenue, led by Germany, the United Kingdom, and Japan.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).